Tislelizumab Combined With Chemotherapy or Radiotherapy in the Treatment of Advanced or Recurrent Metastatic Elderly Esophageal Cancer
To compare the objective response rate (ORR) and safety of tislelizumab combined with chemotherapy and Tislelizumab combined with radiotherapy in elderly patients with esophageal cancer with advanced or recurrent metastasis
Esophageal Cancer
DRUG: Tislelizumab|RADIATION: Radiation|DRUG: Paclitaxel|DRUG: Platinum: cisplatin, carboplatin, naidaplatin and other platinum drugs
objective response rate, Clinical response of treatment according to RESIST v1.1 criteria (ORR, objective response rate)., 12 months
progression free survival, The length of time from enrollment until the time of progression of disease (PFS, progression-free survival)., 12 months
To compare the objective response rate (ORR) and safety of tislelizumab combined with chemotherapy and Tislelizumab combined with radiotherapy in elderly patients with esophageal cancer with advanced or recurrent metastasis